-
Sector Analysis
NewHER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
HER2+/HR+ Breast Cancer Report Overview In the 8MM, there were 107,352 diagnosed incident cases of invasive HER2+/HR+ breast cancer in 2023. The diagnosed incident cases of invasive HER2+/HR+ breast cancer will register an AGR of more than 1% during 2023-2033. HER2+/HR+ Breast Cancer Market Outlook, 2023-2033 (Diagnosed Incident Cases) Buy the Full Report for More Insights into the HER2+/HR+ Breast Cancer Market Forecast Download a Free Report Sample The HER2+/HR+ breast cancer market research report provides an overview of the...
-
Product Insights
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
HER2 Negative Breast Cancer Clinical Trial Analysis Report Overview A total of 2,230 HER2- breast cancer clinical trials were conducted as of February 2024. The HER2- breast cancer clinical trial report provides a comprehensive understanding of the human epidermal growth factor receptor 2 negative breast cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the...
-
Product Insights
Hormone Sensitive Breast Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Hormone Sensitive Breast Cancer - Drugs In Development, 2023’, provides an overview of the Hormone Sensitive Breast Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hormone Sensitive Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...